Pluristem Therapeutics Inc. (NASDAQ: PSTI) today announced interim results from their Phase I clinical trials utilizing their placenta derived cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE